Ark Fintech Innovation ETF (ARKF)

$38.07 0.35 (0.93%)

20:00 EDT ARKF Stock Quote Delayed 30 Minutes

Volume:

Previous Close $38.07

Market Cap 5.73M

PE Ratio -

EPS -

Volume (Avg. Vol.) 1.44M

Day's Range 36.85 - 38.08

52-Week Range 16.94 - 42.33

Dividend & Yield N/A (N/A)

ARKF Stock Predictions, Articles, and Ark Fintech Innovation ETF News

From InvestorPlace
From the Web

3 Great Financial ETFs to Buy for Profits

By Todd Shriber, InvestorPlace Contributor Jul 10, 2020

Rather than investing in individual financial stocks, a risky bet these days, investors may want to consider some unique financial ETFs.

7 ETFs for the End of the Coronavirus

By Todd Shriber, InvestorPlace Contributor Jun 16, 2020

The Covid-19 pandemic dinged a slew of asset classes, but these ETFs are positioned to benefit when the virus is squashed.

7 Fintech ETFs to Buy Now for Fabulous Financial Exposure

By Todd Shriber, InvestorPlace Contributor Aug 20, 2019

When you buy a fintech ETF, you'll be embracing stocks at the forefront of emerging technologies like blockchain and trends such as the gig economy.

5 Fantastic Fintech ETFs to Consider

By Todd Shriber, InvestorPlace Contributor May 14, 2019

The fintech industry is sprawling and encompasses myriad everyday financial function. Here are 5 ways to use ETFs to play the space.

7 Disruptive Tech ETFs to Buy

By Todd Shriber, InvestorPlace Contributor Mar 13, 2019

For investors willing to take on a bit more risk in search of true disruption in the tech space, there are a slew of thematic tech ETFs that offer dedicated exposure to some of the most compelling tech themes; exposure that is hard to come by in traditional tech ETFs.

Carlyle Group invests in health research network TriNetX (NASDAQ:CG)

From Seeking Alpha Sep 21, 2020

Carlyle Group (CG -1.9%) makes an investment in TriNetX, a health research network that aims to optimize clinical research to bring new therapies to market faster, and will acquire a majority stake in the firm.Terms of the transaction weren't disclosed.Equity capital for the investment came from Carlyle Partners VII, an $18.5B fund that makes majority and strategic minority investments primarily in the U.S. in targeted industries, including healthcare.Founded in 2013, TriNetX has built a global network of research hospitals and academic institutions, biotech and pharmaceutical companies, contract research organizations, and other specialty data partners.The firm helps researchers apply a data-driven approach to health research by providing web-based, on-demand access to harmonized global electronic health record, and claims data with a suite of intuitive analytics.

Carlyle to Acquire Data Company TriNetX in Health-Care Drive

From Bloomberg Sep 21, 2020

Carlyle Group Inc., the alternative asset manager overseeing $221 billion, is buying a majority stake in clinical data company TriNetX Inc.

How Covid-19 Permanently Changed the Way Businesses Operate

From Barron's Sep 18, 2020

The Covid-19 pandemic has permanently changed how businesses operate, according to a report from the Carlyle Group.

The Exact Trigger that Indicates Volatility in The Carlyle Group Inc

From Capital Market Laboratories Sep 7, 2020

The Trigger That Turned The Carlyle Group Inc (NASDAQ:CG) Volatility into a Winner.

Technical Short Put Spread Fade the Dip Trade and Trigger in The Carlyle Group Inc

From Capital Market Laboratories Aug 15, 2020

The Techncial Trigger Driven Option Trade Right Before The Carlyle Group Inc (NASDAQ:CG) Earnings.

Carlyle invests in Victory Innovations, maker of disinfecting equipment (NASDAQ:CG)

From Seeking Alpha Sep 16, 2020

Carlyle Group (CG -0.2%) will acquire a majority stake in Victory Innovations, a maker of electrostatic sprayers used to disinfect offices, airplanes, schools, and other facilities, a business that's seen increased demand as a result of the COVID-19 pandemic.Carlyle's investment will help Victory accelerate its growth, including planned expansion in key markets in Asia, Europe, Latin America, and Africa.Terms of the deal weren't disclosed; Carlyle expects it to close by the end of the month.Equity for the transaction will come from Carlyle Partners VII, an $18.5B fund primarily focused on majority and strategic minority investments in the U.S.